Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-dose, single-period, PK study of KP415/d-methylphenidate (d-MPH) capsule in children 6-12 years and adolescents 13-17 years old with ADHD

Trial Profile

A single-dose, single-period, PK study of KP415/d-methylphenidate (d-MPH) capsule in children 6-12 years and adolescents 13-17 years old with ADHD

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Serdexmethylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacokinetics
  • Most Recent Events

    • 18 Jan 2019 According to a KemParma media release, data from this study were presented at the 2019 Annual Meeting of the American Professional Society for ADHD and Related Disorders (APSARD).
    • 17 May 2018 New trial record
    • 10 May 2018 According to a KemParma media release, top-line results were announced by the company.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top